Abbott India Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals

Current Price Action and Market Context

As of 1 January 2026, Abbott India’s stock closed at ₹28,915, up from the previous close of ₹28,509.20. The intraday range saw a high of ₹29,200 and a low of ₹28,600, indicating moderate volatility within a relatively narrow band. The stock remains below its 52-week high of ₹35,921.55 but comfortably above its 52-week low of ₹25,260.20, suggesting a consolidation phase after a period of significant price appreciation.

Comparatively, Abbott India’s returns over various periods reveal a mixed performance against the benchmark Sensex. The stock outperformed the Sensex over the past week with a 1.04% gain versus the Sensex’s 0.22% loss. However, over the one-month and year-to-date periods, Abbott India lagged, declining 3.03% and 2.56% respectively, while the Sensex gained 0.49% and 9.06%. Longer-term returns remain robust, with a 10-year return of 380.93% compared to the Sensex’s 226.30%, underscoring the company’s strong historical growth trajectory.

Technical Indicator Analysis: Mixed Signals Across Timeframes

The technical landscape for Abbott India is nuanced, with several key indicators presenting divergent signals across weekly, monthly, and daily charts. The overall technical trend has shifted from bearish to mildly bearish, reflecting a tentative improvement but still cautionary stance.

MACD (Moving Average Convergence Divergence): The weekly MACD remains bearish, indicating that short-term momentum is still under pressure. Conversely, the monthly MACD is mildly bearish, suggesting that longer-term momentum is stabilising but not yet bullish. This divergence implies that while immediate price action is weak, the broader trend may be bottoming out.

RSI (Relative Strength Index): The weekly RSI is bullish, signalling that the stock is gaining upward momentum in the short term and may be recovering from oversold conditions. However, the monthly RSI shows no clear signal, indicating a lack of decisive momentum over the longer term. This mixed RSI reading suggests that while short-term buying interest is increasing, the stock has yet to establish a sustained uptrend.

Bollinger Bands: On the weekly chart, Bollinger Bands indicate a mildly bearish stance, with the stock price hovering near the lower band, reflecting subdued volatility and potential downside risk. The monthly Bollinger Bands are bearish, reinforcing the notion of longer-term pressure on price levels.

Moving Averages: Daily moving averages remain bearish, with the stock trading below key averages such as the 50-day and 200-day moving averages. This technical setup typically signals that the stock is in a downtrend in the short term, requiring a break above these averages to confirm a reversal.

KST (Know Sure Thing): The weekly KST is mildly bullish, indicating improving momentum and potential for a short-term rally. However, the monthly KST remains mildly bearish, consistent with the broader caution observed in monthly indicators.

Dow Theory: Weekly Dow Theory signals are mildly bullish, suggesting that the stock may be forming a base or beginning a new upward phase. Monthly Dow Theory remains mildly bearish, reflecting the need for further confirmation before a sustained uptrend can be declared.

On-Balance Volume (OBV): Both weekly and monthly OBV show no clear trend, indicating that volume is not strongly confirming price movements. This lack of volume confirmation adds to the uncertainty surrounding the stock’s near-term direction.

Mojo Score and Rating Upgrade

MarketsMOJO has upgraded Abbott India’s Mojo Grade from Sell to Hold as of 29 December 2025, reflecting an improved outlook based on technical and fundamental factors. The current Mojo Score stands at 50.0, signalling a neutral stance. The Market Cap Grade is 2, indicating a mid-cap valuation tier within the Pharmaceuticals & Biotechnology sector.

This upgrade suggests that while the stock is not yet a strong buy, it has stabilised sufficiently to warrant investor attention for potential accumulation, especially if technical indicators continue to improve.

Sector and Industry Context

Abbott India operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory challenges, and evolving market dynamics. The sector has seen mixed performance recently, with some companies benefiting from increased healthcare spending and others facing headwinds from pricing pressures and supply chain disruptions.

Abbott India’s relative underperformance versus the Sensex over the past month and year-to-date periods highlights the challenges faced by the company in maintaining momentum amid sector volatility. However, its strong long-term returns and recent technical stabilisation indicate resilience and potential for recovery.

Investor Implications and Outlook

For investors, the current technical signals suggest a cautious approach. The weekly bullish RSI and mildly bullish KST and Dow Theory indicators offer some hope for a short-term rebound. However, the persistent bearish signals from MACD, moving averages, and Bollinger Bands on monthly and daily charts caution against aggressive buying.

Traders may consider monitoring key resistance levels near the daily moving averages and the 52-week high of ₹35,921.55 for signs of a sustained breakout. Conversely, support near the 52-week low of ₹25,260.20 remains critical to watch for downside risk.

Given the mixed technical picture, a Hold rating aligns with the current market environment, suggesting investors maintain positions but await clearer confirmation before increasing exposure.

Conclusion: Navigating a Transitional Phase

Abbott India Ltd. is currently navigating a transitional phase in its technical momentum, marked by a shift from bearish to mildly bearish trends and a complex array of indicator signals. While short-term momentum indicators such as the weekly RSI and KST suggest potential for recovery, longer-term measures remain cautious.

Investors should weigh the company’s strong historical returns and recent rating upgrade against the current technical uncertainties. Maintaining a Hold position while monitoring key technical levels and sector developments appears prudent at this juncture.

As the Pharmaceuticals & Biotechnology sector continues to evolve, Abbott India’s ability to capitalise on emerging opportunities and overcome sector headwinds will be critical to its future price momentum and investor returns.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today